The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

  • See Evidence submitted by expert panel for details.

Variant: NM_000152.4(GAA):c.2242dup (p.Glu748Glyfs)

CA8815662

370651 (ClinVar)

Gene: GAA
Condition: glycogen storage disease II
Inheritance Mode: Autosomal recessive inheritance
UUID: 449da1e5-c230-4287-9b50-169d8d509dbf
Approved on: 2020-05-04
Published on: 2020-05-26

HGVS expressions

NM_000152.4:c.2242dup
NM_000152.4(GAA):c.2242dup (p.Glu748Glyfs)
NC_000017.11:g.80117020dup
CM000679.2:g.80117020dup
NC_000017.10:g.78090819dup
CM000679.1:g.78090819dup
NC_000017.9:g.75705414dup
NG_009822.1:g.20465dup
NM_000152.3:c.2242dup
NM_001079803.1:c.2242dup
NM_001079804.1:c.2242dup
NM_001079803.2:c.2242dup
NM_001079804.2:c.2242dup
NM_000152.5:c.2242dup
NM_001079803.3:c.2242dup
NM_001079804.3:c.2242dup
ENST00000302262.7:c.2242dup
ENST00000390015.7:c.2242dup
ENST00000572080.1:n.661dup
ENST00000573556.1:n.195dup

Pathogenic

Met criteria codes 3
PP4 PM2 PVS1
Not Met criteria codes 1
PM3

Evidence Links 4

Expert Panel

Criteria Specification Information

Criteria Specifications for this VCEP
Evidence submitted by expert panel
Lysosomal Diseases VCEP
This variant, c.2242dup (p.Glu748Glyfs), is a frameshift variant predicted to cause a premature termination codon, nonsense mediated decay, and lack of gene product, meeting PVS1. The highest population minor allele frequency in gnomAD is 0.00001767 in the European, non-Finnish, population, meeting PM2. This variant has been reported in at least 2 individuals with Pompe disease and deficient GAA activity meeting the ClinGen LSD VCEP’s PP4 specifications (PMIDs 9535769, 21484825). Both of these individuals are compound heterozygous for the variant and a unique variant, phase unknown; either c.1933G>A (p.Asp645Asn) (PMID 9535769) or c.1195-8G>A (PMID 21484825). In both cases, the in trans data from these patients will be used in the assessment of the second variant and was not included here in order to avoid a circular argument. There is a ClinVar entry for this variant (Variation ID 370651; 2 star review status) with three submitters classifying the variant and pathogenic, and one as likely pathogenic. In summary, this variant meets the criteria to be classified as pathogenic for Pompe Disease. GAA-specific ACMG/AMP criteria applied, as specified by the ClinGen LSD VCEP: PVS1, PM2, PP4.
Met criteria codes
PP4
At least 2 individuals have been reported with this variant and GAA activity <30% normal in cultured fibroblasts (PMIDs 9535769, 21484825). This meets the specifications for PP4.

PM2
The highest population minor allele frequency in gnomAD v2.1.1 is 0.00001767 (European, non-Finnish) which is lower than the ClinGen LSD VCEP threshold (<0.001) for PM2, meeting this criterion.
PVS1
This is a frameshift variant which is predicted to result in a premature termination codon and nonsense mediated decay resulting in no gene product.
Not Met criteria codes
PM3
This variant has been reported in at least 2 individuals with Pompe disease and deficient GAA activity meeting the ClinGen LSD VCEP’s PP4 specifications (PMIDs 9535769, 21484825). Both of these individuals are compound heterozygous for the variant and a unique variant, phase unknown; either c.1933G>A (p.Asp645Asn) (PMID 9535769) or c.1195-8G>A (PMID 21484825). In both cases, the in trans data from these patients will be used in the assessment of the second variant and was not included here in order to avoid a circular argument.

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.
¤ Powered by BCM's Genboree.